It inhibits cancer by blocking ligand binding, receptor activation / phosphorylation, and downstream signaling and has also shown a unique ability to cetuximab and panitumumab, of the EGFR receptors from the cancer cell surface by inducing EGFR internalization and degradation induced in preclinical studies. In preclinical studies Sym004 was significantly more effective than the two marketed EGFR inhibitors, cetuximab and panitumumab, and has the potential to treat, tumors with acquired resistance to EGFR-targeted other means, including both monoclonal antibodies and small molecule tyrosine kinase inhibitors..
Sym004 is a novel drug candidates on a 1:1 mixture of two monoclonal anti-EGFR antibodies porter against different epitopes directed in EGFR extracellular domain III-based.. Separately, Symphogen said that preclinical data has been highlighted to demonstrate the superiority of the now proprietary Sym004 to the reference monoclonal antibody today in Paris, France in a plenary session of the 9th International Symposium on Targeted Cancer Therapies .Bionovo,Bionovo be a pharmaceutical company which to the discovery and development of safe and effective treatment to women’s health and Krebs, use of forward – significant unmet needs and million potential annual revenues focuses. The company applies its expert in the biology of postmenopausal and cancer make new medicines from botanical sources, to create novel mechanisms inferred. Based on the findings the early and mid phase of clinical trials, Bionovo thinks it new classes of product candidates in their rich pipeline with the potential to in their respective markets discovered to be the leader. In Emeryville in Emeryville, California and is listed on NASDAQ Capital Market under the symbol ‘BNVI ‘.
– the understanding of the veterinary role in food production supply chain with veterinary students and the prominence of foods of animal production in the veterinary syllabus;.